Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Elena Rubets"'
Autor:
Vinitha N. Ragavan, Pramod C. Nair, Natalia Jarzebska, Ramcharan Singh Angom, Luana Ruta, Elisa Bianconi, Silvia Grottelli, Natalia D. Tararova, Daniel Ryazanskiy, Steven R. Lentz, Sara Tommasi, Jens Martens-Lobenhoffer, Toshiko Suzuki-Yamamoto, Masumi Kimoto, Elena Rubets, Sarah Chau, Yingjie Chen, Xinli Hu, Nadine Bernhardt, Peter M. Spieth, Norbert Weiss, Stefan R. Bornstein, Debabrata Mukhopadhyay, Stefanie M. Bode-Böger, Renke Maas, Ying Wang, Antonio Macchiarulo, Arduino A. Mangoni, Barbara Cellini, Roman N. Rodionov
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-16 (2023)
Abstract Dimethylarginine dimethylaminohydrolase 1 (DDAH1) protects against cardiovascular disease by metabolising the risk factor asymmetric dimethylarginine (ADMA). However, the question whether the second DDAH isoform, DDAH2, directly metabolises
Externí odkaz:
https://doaj.org/article/c46891e5d10241cf95a530af2ca4d6b5
Autor:
Roman N. Rodionov, Natalia Jarzebska, Dmitrii Burdin, Vladimir Todorov, Jens Martens-Lobenhoffer, Anja Hofmann, Anne Kolouschek, Nada Cordasic, Johannes Jacobi, Elena Rubets, Henning Morawietz, John F. O’Sullivan, Alexander G. Markov, Stefan R. Bornstein, Karl Hilgers, Renke Maas, Christian Pfluecke, YingJie Chen, Stefanie M. Bode-Böger, Christian P. M. Hugo, Bernd Hohenstein, Norbert Weiss
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-13 (2022)
Abstract Elevated plasma concentrations of asymmetric dimethylarginine (ADMA) are associated with an increased risk of mortality and adverse cardiovascular outcomes. ADMA can be metabolized by dimethylarginine dimethylaminohydrolases (DDAHs) and by a
Externí odkaz:
https://doaj.org/article/674f7781bc76496db8e890262bf3eaf5
Autor:
Alena A. Kozlova, Elena Rubets, Magdalini R. Vareltzoglou, Natalia Jarzebska, Vinitha N. Ragavan, Yingjie Chen, Jens Martens-Lobenhoffer, Stefanie M. Bode-Böger, Raul R. Gainetdinov, Roman N. Rodionov, Nadine Bernhardt
Publikováno v:
Journal of Neural Transmission.
The enzyme dimethylarginine dimethylaminohydrolase 1 (DDAH1) plays a pivotal role in the regulation of nitric oxide levels by degrading the main endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA). Growing evidence highlight
Autor:
Norbert Weiss, Alexander G. Markov, Anja Hofmann, Jens Martens-Lobenhoffer, Natalia Jarzebska, Yingjie Chen, Elena Rubets, Christian Pfluecke, Dmitrii V Burdin, Vladimir T. Todorov, Roman N. Rodionov, Bernd Hohenstein, Nada Cordasic, Karl F. Hilgers, Christian P . M. Hugo, Stefan R. Bornstein, Henning Morawietz, John F. O'Sullivan, Anne Kolouschek, Stefanie M. Bode-Böger, Johannes Jacobi, Renke Maas
Publikováno v:
Scientific Reports. 12
Objective: Elevated plasma concentrations of asymmetric dimethylarginine (ADMA) are associated with an increased risk of mortality and adverse cardiovascular outcomes. ADMA can be metabolized by dimethylarginine dimethylaminohydrolases (DDAHs) and by
Divergent dimethylarginine dimethylaminohydrolase isoenzyme expression in the central nervous system
Autor:
Michael Bauer, Iana Vadimovna Lukianova, Elena Rubets, Toshiko Suzuki-Yamamoto, Roman N. Rodionov, Natalia Jarzebska, Vinitha Nair Ragavan, Norbert Weiss, Alena Kozlova, Masumi Kimoto, Arduino A. Mangoni, Raul R. Gainetdinov, Alexander G. Markov, Anastasia E. Bikmurzina, Nadine Bernhardt
The endogenous methylated derivative of ʟ-arginine, Nω,Nω′-dimethyl-ʟ-arginine (asymmetric dimethylarginine, ADMA), an independent risk factor in many diseases, inhibits the activity of nitric oxide synthases and, consequently, modulates the av
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7a08f060c2c750029c73fcf9af59dcf
https://doi.org/10.21203/rs.3.rs-148653/v1
https://doi.org/10.21203/rs.3.rs-148653/v1